EGFR and non-small cell lung carcinoma: Only low percentages of patients with EGFR mutation (7% –15%) or ALK translocation (<1%–4%) had been included in phase III trials on ICI for NSCLC.[30–32] Subgroup analyses of survival data concerned patients with EGFR mutations, but not ALK translocation because of their small numbers.